One of Kite Pharma’s CAR-T patients died from cerebral edema, triggering a safety alarm
Kite Pharma revealed today that one of the patients in their late-stage program for the CAR-T drug KTE-C19 died from cerebral edema, the same brain swelling condition that went on to scuttle Juno Therapeutics’ lead drug.
In a call with analysts for their Q1 report, the closely-watched biotech $KITE said that they had informed the FDA and there was no pause or halt to the study. The death in late April, though, clearly raised a red flag for analysts after Kite had managed to get all the way through a pivotal program without a death due to cerebral edema after treating hundreds of patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.